Providence First Trust Co Purchases 3,449 Shares of iShares Biotechnology ETF $IBB

Providence First Trust Co purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,449 shares of the financial services provider’s stock, valued at approximately $726,000.

Several other hedge funds have also made changes to their positions in IBB. Horizon Wealth Management LLC increased its stake in iShares Biotechnology ETF by 49.5% in the third quarter. Horizon Wealth Management LLC now owns 90,107 shares of the financial services provider’s stock valued at $18,970,000 after purchasing an additional 29,822 shares during the last quarter. Kestra Advisory Services LLC boosted its stake in iShares Biotechnology ETF by 34.1% in the 3rd quarter. Kestra Advisory Services LLC now owns 63,312 shares of the financial services provider’s stock worth $13,329,000 after buying an additional 16,117 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in iShares Biotechnology ETF by 1.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 139,653 shares of the financial services provider’s stock worth $29,401,000 after buying an additional 1,819 shares during the last quarter. Compass Financial Management LLC grew its holdings in iShares Biotechnology ETF by 76.0% in the 3rd quarter. Compass Financial Management LLC now owns 521 shares of the financial services provider’s stock valued at $110,000 after buying an additional 225 shares during the period. Finally, Provenance Wealth Advisors LLC purchased a new stake in iShares Biotechnology ETF in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 1.7%

Shares of NASDAQ IBB traded up $3.64 on Friday, reaching $213.63. 2,163,900 shares of the company traded hands, compared to its average volume of 1,851,928. iShares Biotechnology ETF has a fifty-two week low of $154.98 and a fifty-two week high of $222.29. The company has a 50 day moving average of $208.46 and a 200 day moving average of $185.91.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were issued a $0.0112 dividend. The ex-dividend date was Tuesday, September 15th. This is a negative change from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. This represents a $0.04 dividend on an annualized basis and a yield of 0.0%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.